X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Syfovre (pegcetacoplan) is the first and only approved therapy for geographic atrophy (GA). It targets C3 to provide comprehensive control of the complement cascade, part of the body’s immune system.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Ophthalmology Product Name: Syfovre
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2024
Details:
Syfovre (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). It targets C3 to provide comprehensive control of the complement cascade, part of the body’s immune system.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Ophthalmology Product Name: Syfovre
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 14, 2023
Details:
Empaveli (pegcetacoplan) Injector is a compact, single-use, on-body device designed to enhance self-administration, which is indicated for treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
Lead Product(s): Pegcetacoplan
Therapeutic Area: Rare Diseases and Disorders Product Name: Empaveli
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 02, 2023
Details:
Syfovre™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). It targets C3 to provide comprehensive control of the complement cascade, part of the body’s immune system.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Neurology Product Name: Syfovre
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2023
Details:
Syfovre™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). It targets C3 to provide comprehensive control of the complement cascade, part of the body’s immune system.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Ophthalmology Product Name: Syfovre
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2023
Details:
The net proceeds will be used to support the commercialization of Empaveli (pegcetacoplan) and Syfovre, to fund clinical development of our current and future product candidates, to conduct research activities and for working capital and other general corporate purposes.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Rare Diseases and Disorders Product Name: Empaveli
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan Securities
Deal Size: $402.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 27, 2023
Details:
The company intend to use the net proceeds, to support the commercialization of Empaveli (pegcetacoplan) and SYFOVRE, to fund clinical development of their current and future product candidates and to conduct research activities.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Rare Diseases and Disorders Product Name: Empaveli
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 22, 2023
Details:
Syfovre™ (pegcetacoplan injection) is the first and only approved therapy for geographic atrophy (GA). It targets C3 to provide comprehensive control of the complement cascade, part of the body’s immune system.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Ophthalmology Product Name: Syfovre
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
Empaveli™ having pegcetacoplan, is a targeted C3 therapy designed to regulate the activity of the complement cascade, which can lead to the onset and progression of many serious diseases.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Rare Diseases and Disorders Product Name: Empaveli
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Swedish Orphan Biovitrum AB
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2022
Details:
APL-2 (Pegcetacoplan) is an investigational, targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious diseases.
Lead Product(s): Pegcetacoplan
Therapeutic Area: Ophthalmology Product Name: APL-2
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
